Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions

Clinical Pharmacokinetics

Volumn 42, Issue 8, 2003, Pages 765-777

  Bredberg, Eva ^a   Andersson, Tommy B ^a   Frison, Lars ^a   Thuresson, Annelie ^a   Johansson, Susanne ^a   Eriksson Lepkowska, Maria ^a   Larsson, Marita ^a   Eriksson, Ulf G ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DIAZEPAM; DICLOFENAC; ISOENZYME; LIVER ENZYME; MELAGATRAN; NIFEDIPINE; THROMBIN INHIBITOR; XIMELAGATRAN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG SCREENING; HUMAN; LIVER MICROSOME; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADMINISTRATION, ORAL; ADULT; AGED; AMIDINES; ANTICOAGULANTS; AREA UNDER CURVE; AZETIDINES; BENZYLAMINES; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DIAZEPAM; DICLOFENAC; DRUG INTERACTIONS; GLYCINE; HUMANS; INFUSIONS, INTRAVENOUS; MICROSOMES, LIVER; MIDDLE AGED; NIFEDIPINE; NORDAZEPAM; PRODRUGS; THROMBIN;

EID: 0042623846     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200342080-00005     Document Type: Article

References (27)

1. Eriksson UG, Bredberg U, Hoffmann K-J, et al. Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. Drug Metab Dispos 2003; 31: 294-305
2. Eriksson UG, Bredburg U, Gislén K, et al. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young, healthy male subjects. Eur J Clin Pharmacol 2003; 59:35-43
3. Sarich TC, Eriksson UG, Mattsson C, et al. Inhibition of thrombin generation by the oral direct thrombin inhibitor ximelagatran in shed blood from healthy male subjects. Thromb Haemost 2002; 87: 300-5
4. Gustafsson D, Antonsson T, Bylund R, et al. Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb Haemost 1998; 79: 110-8
5. Gustafsson D, Nyström J, Carlsson S, et al. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 2001; 101: 171-81
6. Elg M, Gustafsson D, Deinum J. The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis. Thromb Haemost 1997; 78: 1286-92
7. Elg M, Gustafsson D, Carlsson S. Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat. Thromb Res 1999; 94: 187-97
8. Mehta JL, Chen L, Nichols WW, et al. Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery. J Cardiovasc Pharmacol 1998; 31: 345-51
9. Eriksson BI, Carlsson S, Halvarsson M, et al. Antithrombotic effect of two low molecular weight thrombin inhibitors and a low-molecular weight heparin in a caval vein thrombosis model in the rat. Thromb Haemost 1997; 78: 1404-7
10. Mattsson C, Björkman J-A, Ulvinge J-C. Melagatran, hirudin and heparin as adjuncts to tissue-type plasminogen activator in a canine model of coronary artery thrombolysis. Fibrinolysis Proteolysis 1997; 11: 121-8
11. Eriksson BI, Arfwidsson A-C, Frison L, et al. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery. Thromb Haemost 2002; 87: 231-7
12. Eriksson BI, Bergqvist D, Kälebo P, et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 2002; 360: 1441-7
13. Francis CW, Davidson BL, Berkowitz SD, et al. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind trial. Ann Intern Med 2002; 137: 648-55
14. Eriksson BI, Agnelli G, Cohen AT, et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement: The METHRO III study. Thromb Haemost 2003; 89: 288-96
15. Heit JA, Colwell CW, Francis CW, et al. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. Arch Intern Med 2001; 161: 2215-21
16. Francis CW, Berkowitz SD, Comp PC, et al. Randomized, double-blind, comparison of ximelagatran, an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism (VTE) after total knee replacement (TKR) [abstract]. Blood 2002; 100 (11): 82a
17. Eriksson H, Wåhlander K, Gustafsson D, et al. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J Thromb Haemost 2003; 1: 41-7
18. Petersen P, Grind M, Adler J, SPORTIF II Investigators. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: SPORTIF II. a dose-guiding, tolerability and safety study. J Am Coll Cardiol 2003; 42: 1445-51
19. Formation of melagatran from H 415/04 in human intestine, kidney and lung microsomes. Mölndal: DMPK and Bioanalytical Chemistry, AstraZeneca, 2000. (Data on file)
20. Andersson TB. Activation of ximelagatran, melagatran's prodrug [abstract]. Drug Metab Rev 2001; 33 Suppl. 1: 8
21. Bapiro TE, Egnell AC, Hasler JA, et al. Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos 2001; 29: 30-5
22. Masimirembwa CM, Otter C, Berg M, et al. Heterologous expression and kinetic characterization of human cytochrome P-450: validation of a pharmaceutical tool for drug metabolism research. Drug Metab Dispos 1999; 27: 1117-21
23. Larsson M, Lögren U, Ahnoff M, et al. Determination of melagatran, a novel, direct thrombin inhibitor, in human plasma and urine by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 766: 47-55
24. Guengerich FP. Role of cytochrome P450 enzymes in drug-drug interactions. Adv Pharmacol 1997; 43: 7-35
25. The effect of oral H 376/95 on the pharmacokinetics of diclofenac in healthy male volunteers. Mölndal: Experimental Medicine, AstraZeneca, 2002. (Data on file)
26. Morin S, Loriot MA, Poirier JM, et al. Is diclofenac a valuable CYP2C9 probe in humans? Eur J Clin Pharmacol 2001; 56: 793-7
27. Andersson T, Miners JO, Veronese ME, et al. Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. Br J Clin Pharmacol 1994; 38: 131-7